Abstract
Background CGM-based tracking is expanding in non-diabetic groups to meet wellness and preventive care needs. However, data is limited on short-term outcomes for glycemic control, insulin resistance and correlation of algorithm-derived score to known glycemic metrics in controlled settings, making benchmarking difficult. This is especially true for the high-risk Indian/South Asian demographic.
Objectives To examine changes resulting from the Ultrahuman (UH) M1 CGM application-with concomitant FitBit tracker use in patterns of glucose variability (GV). Evaluate GV correlations with stress, sleep duration, inflammation, and activity. Examine correlations between UH metabolic score (UH-MS) and biomarkers of dysglycemia and insulin resistance.
Methods Participants (N=53 non-diabetic, 52 pre-diabetic) wore the UH-M1 CGM and FitBit tracker for a 14-day period. HsCRP, cortisol, OGTT, HbA1c, HOMA-IR levels, and standard blood profile measurements were obtained.
Results Mean glucose levels, restricted time in range (70-110mg/dL), and GV metrics were significantly different between non- and pre-diabetics and displayed improvements with M1 use. Strong correlations of specific GV metrics with inflammation were found in pre-diabetics, with modest correlation between sleep and activity in non-diabetics. Elevated HOMA-IR, HbA1c, and OGTT were linked with J-index and high blood glucose index in pre-diabetics, and low blood glucose index in non-diabetics. UH-MS displayed a strong inverse relationship with insulin resistance and glucose dysregulation.
Conclusions The study presents the first guidance values of glycemic indices of non- and pre-diabetic Indians and supports the notion that short-duration CGM use with algorithm scores can affect positive changes in glucose management.
Competing Interest Statement
Conflicting interests: B.S, V.S., and M.K. are stakeholders in Ultrahuman Healthcare Private Limited. M.C. was a full-time employee of Ultrahuman during the study and analysis period. M.K. and V.S. declare no other conflict of interest. B.S. is a stakeholder of Triomics Healthcare.
Clinical Trial
CTRI/2022/08/044808
Funding Statement
The study was sponsored by Ultrahuman Healthcare Pvt. Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the ethics committees of all the participating centers. The details of the trial site,ethics committee, and date of approval are provided in a tabular format in Supplementary Table 7 in main text and mentioned as below. -Hospital Ethics Board of Aakash Healthcare Private Limited, Delhi gave approval for this study on 11th August 2022. - Universal Ethics Committee of Aadhavvan Diabetes and Research Centre, Chennai, Tamil Nadu gave approval for this study on 8th August 2022. -Diabetes Centre Ethics Committee of Belgaum Diabetes Centre, Belgaum, Karnataka, gave approval for this study on 12th August 2022. -Bangalore Ethics Committee, gave approval on 26th September 2022, for Suresh Diacare Clinic, Bangalore, Karnataka site. -Shrey Hospital Institutional Ethics Committee for Diacare Research, Ahmedabad, Gujarat, gave approval for this study on 12th August 2022. - Hospital Ethics Committee of Vinaya Hospital, Mangaluru, Karnataka, gave approval for this study on 30th July 2022. -Institutional Ethics Committee of Induss Hospital, Hyderabad, Telengana, gave approval for this study on 14th October 2022. -Bangalore Ethics Committee, gave approval on 3rd October 2022, for Kulkarni's MedZonne, Bangalore, Karnataka site. -Good Society Ethical Research Oversight Committee of Naveda Hospital, Delhi, gave approval for the study on 2nd August 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Inclusion of principal investigator names in the acknowledgement section. Correction of co-author name.
Data availability
Study outcomes data can be made available upon reasonable request. The M1 and MS platform codes and technical details are proprietary assets of Ultrahuman and will not be disclosed.
